The Ensign Group, Inc. (ENSG) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1153729,
    "name": "The Ensign Group, Inc.",
    "stock_name": "The Ensign Group, Inc.",
    "full_name": "The Ensign Group, Inc.",
    "name_url": "stocks-analysis/the-ensign-group-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "175.36",
    "chg": -1.73,
    "chgp": "-0.98%",
    "dir": -1,
    "prev_price": "177.09",
    "mcapval": "10,536.38",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US29358P1012",
    "curr_date": "Dec 16",
    "curr_time": "",
    "bse_nse_vol": "363.28 k",
    "exc_status": "Active",
    "traded_date": "Dec 16, 2025",
    "traded_date_str": "2025 12 16",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/the-ensign-group-inc-1153729-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "The Ensign Group Hits New 52-Week High of $193.84",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/the-ensign-group-hits-new-52-week-high-of-19384-3674019",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/TheEnsignGroupI_priceRelatedfactors_3674019.png",
        "date": "2025-11-05 16:40:48",
        "description": "The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 10,536 million, the company exhibits solid financial health, marked by a low debt-to-equity ratio and impressive growth in net sales and operating profit."
      },
      {
        "title": "The Ensign Group Hits New 52-Week High of USD 188.25",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/the-ensign-group-hits-new-52-week-high-of-usd-18825-3649249",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/TheEnsignGroupI_priceRelatedfactors_3649249.png",
        "date": "2025-10-27 16:51:31",
        "description": "The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a 55.81% return over the past year. With a market capitalization of USD 10,536 million, the company demonstrates financial stability, efficiency, and robust growth metrics in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "The Ensign Group Experiences Revision in Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ensign-groups-valuation-grade-upgraded-from-fair-to-attractive-amid-strong-financial-metrics-3648993",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/TheEnsignGroupI_valuationdot_3648993.png",
        "date": "2025-10-27 15:41:41",
        "description": "The Ensign Group, Inc. has recently adjusted its valuation, reflecting its financial metrics and market position. With a P/E ratio of 30 and a PEG ratio of 0.36, the company demonstrates a favorable growth outlook. Its competitive valuation metrics highlight its strength relative to industry peers."
      },
      {
        "title": "Ensign Group's Valuation Upgrade Highlights Strong Financial Performance and Growth Potential",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/the-ensign-group-upgraded-to-buy-following-improved-valuation-and-strong-financial-performance-3640223",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/TheEnsignGroupI_mojoScore_3640223.png",
        "date": "2025-10-23 15:47:17",
        "description": "The Ensign Group, Inc. has recently experienced a change in its valuation grade, now deemed attractive. Key financial metrics reveal strong operational efficiency, healthy growth in net sales and operating profit, and solid figures for cash flow and interest coverage, highlighting the company's financial stability."
      },
      {
        "title": "Is The Ensign Group, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-the-ensign-group-inc-overvalued-or-undervalued-3637628",
        "imagepath": "",
        "date": "2025-10-21 12:06:01",
        "description": "As of 17 October 2025, The Ensign Group, Inc. has moved from a very expensive valuation grade to attractive. Based on the current metrics, the company appears to be undervalued. Key valuation ratios include a P/E ratio of 30, an EV to EBITDA of 19.44, and a PEG ratio of 0.36, which suggests that the stock may offer growth potential relative to its price.\n\nIn comparison to peers, The Ensign Group's P/E ratio of 30 is higher than Encompass Health Corp.'s 20.94, but lower than its own previous valuation. The EV to EBITDA ratio of 19.44 is also more favorable than the risky DaVita, Inc.'s 7.56, indicating a stronger operational performance. Although return data is not available for a direct comparison with the S&P 500, the recent grade change and attractive valuation suggest a positive outlook for the stock...."
      },
      {
        "title": "The Ensign Group Experiences Revision in Stock Evaluation Amid Strong Financial Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/the-ensign-groups-valuation-grade-changes-from-very-expensive-to-attractive-3640640",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/TheEnsignGroupI_valuationdot_3640640.png",
        "date": "2025-10-20 15:58:11",
        "description": "The Ensign Group, Inc. has recently adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 30 and a PEG ratio of 0.36. With a robust ROCE of 20.77% and a year-to-date return of 37.02%, the company demonstrates effective capital management and competitive positioning in its sector."
      },
      {
        "title": "Is The Ensign Group, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-the-ensign-group-inc-overvalued-or-undervalued-3634499",
        "imagepath": "",
        "date": "2025-10-20 12:23:31",
        "description": "As of 17 October 2025, the valuation grade for The Ensign Group, Inc. moved from very expensive to attractive, indicating a significant improvement in its perceived value. The company appears undervalued, supported by a P/E ratio of 30, a PEG ratio of 0.36, and an EV to EBITDA ratio of 19.44. In comparison, Encompass Health Corp. has a P/E of 20.94 and an EV to EBITDA of 12.89, while Option Care Health, Inc. shows a P/E of 23.61 and an EV to EBITDA of 14.37, suggesting that The Ensign Group is trading at a premium relative to some peers.\n\nThe Ensign Group has demonstrated strong performance with a year-to-date return of 37.02%, significantly outperforming the S&P 500's return of 13.30% over the same period. This performance reinforces the narrative that the stock may be undervalued in light of its attractive valuation metrics and solid returns...."
      },
      {
        "title": "Is The Ensign Group, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-the-ensign-group-inc-overvalued-or-undervalued-3632038",
        "imagepath": "",
        "date": "2025-10-19 12:01:03",
        "description": "As of 17 October 2025, the valuation grade for The Ensign Group, Inc. has moved from very expensive to attractive, indicating a significant improvement in its perceived value. The company appears to be undervalued, particularly given its P/E ratio of 30, which is higher than the industry average, and a PEG ratio of 0.36, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 19.44, which is competitive compared to peers like Encompass Health Corp. with a P/E of 20.94 and EV to EBITDA of 12.89.\n\nIn terms of performance, The Ensign Group has outperformed the S&P 500 across multiple periods, with a year-to-date return of 37.02% compared to the S&P 500's 13.30%. This strong performance reinforces the attractiveness of the stock, particularly in light of its solid ROCE of 20.77% and ROE of 16.14%, which further highlight its operational efficiency and profitabili..."
      },
      {
        "title": "The Ensign Group Hits New 52-Week High of $179.27",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/the-ensign-group-hits-new-52-week-high-of-17927-3622775",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/TheEnsignGroupI_priceRelatedfactors_3622775.png",
        "date": "2025-10-15 16:54:32",
        "description": "The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly above the S&P 500. The company showcases robust financial metrics, including a solid return on equity and low debt-to-equity ratio, alongside consistent positive results in sales and operating profit growth."
      }
    ],
    "total": 18,
    "sid": "1153729",
    "stock_news_url": "https://www.marketsmojo.com/news/the-ensign-group-inc-1153729"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

The Ensign Group Hits New 52-Week High of $193.84

2025-11-05 16:40:48

The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 10,536 million, the company exhibits solid financial health, marked by a low debt-to-equity ratio and impressive growth in net sales and operating profit.

The Ensign Group Hits New 52-Week High of USD 188.25

2025-10-27 16:51:31

The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a 55.81% return over the past year. With a market capitalization of USD 10,536 million, the company demonstrates financial stability, efficiency, and robust growth metrics in the Pharmaceuticals & Biotechnology sector.

The Ensign Group Experiences Revision in Stock Evaluation Amid Competitive Market Landscape

2025-10-27 15:41:41

The Ensign Group, Inc. has recently adjusted its valuation, reflecting its financial metrics and market position. With a P/E ratio of 30 and a PEG ratio of 0.36, the company demonstrates a favorable growth outlook. Its competitive valuation metrics highlight its strength relative to industry peers.

Ensign Group's Valuation Upgrade Highlights Strong Financial Performance and Growth Potential

2025-10-23 15:47:17

The Ensign Group, Inc. has recently experienced a change in its valuation grade, now deemed attractive. Key financial metrics reveal strong operational efficiency, healthy growth in net sales and operating profit, and solid figures for cash flow and interest coverage, highlighting the company's financial stability.

Is The Ensign Group, Inc. overvalued or undervalued?

2025-10-21 12:06:01

As of 17 October 2025, The Ensign Group, Inc. has moved from a very expensive valuation grade to attractive. Based on the current metrics, the company appears to be undervalued. Key valuation ratios include a P/E ratio of 30, an EV to EBITDA of 19.44, and a PEG ratio of 0.36, which suggests that the stock may offer growth potential relative to its price. In comparison to peers, The Ensign Group's P/E ratio of 30 is higher than Encompass Health Corp.'s 20.94, but lower than its own previous valuation. The EV to EBITDA ratio of 19.44 is also more favorable than the risky DaVita, Inc.'s 7.56, indicating a stronger operational performance. Although return data is not available for a direct comparison with the S&P 500, the recent grade change and attractive valuation suggest a positive outlook for the stock....

The Ensign Group Experiences Revision in Stock Evaluation Amid Strong Financial Performance

2025-10-20 15:58:11

The Ensign Group, Inc. has recently adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 30 and a PEG ratio of 0.36. With a robust ROCE of 20.77% and a year-to-date return of 37.02%, the company demonstrates effective capital management and competitive positioning in its sector.

Is The Ensign Group, Inc. overvalued or undervalued?

2025-10-20 12:23:31

As of 17 October 2025, the valuation grade for The Ensign Group, Inc. moved from very expensive to attractive, indicating a significant improvement in its perceived value. The company appears undervalued, supported by a P/E ratio of 30, a PEG ratio of 0.36, and an EV to EBITDA ratio of 19.44. In comparison, Encompass Health Corp. has a P/E of 20.94 and an EV to EBITDA of 12.89, while Option Care Health, Inc. shows a P/E of 23.61 and an EV to EBITDA of 14.37, suggesting that The Ensign Group is trading at a premium relative to some peers. The Ensign Group has demonstrated strong performance with a year-to-date return of 37.02%, significantly outperforming the S&P 500's return of 13.30% over the same period. This performance reinforces the narrative that the stock may be undervalued in light of its attractive valuation metrics and solid returns....

Is The Ensign Group, Inc. overvalued or undervalued?

2025-10-19 12:01:03

As of 17 October 2025, the valuation grade for The Ensign Group, Inc. has moved from very expensive to attractive, indicating a significant improvement in its perceived value. The company appears to be undervalued, particularly given its P/E ratio of 30, which is higher than the industry average, and a PEG ratio of 0.36, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 19.44, which is competitive compared to peers like Encompass Health Corp. with a P/E of 20.94 and EV to EBITDA of 12.89. In terms of performance, The Ensign Group has outperformed the S&P 500 across multiple periods, with a year-to-date return of 37.02% compared to the S&P 500's 13.30%. This strong performance reinforces the attractiveness of the stock, particularly in light of its solid ROCE of 20.77% and ROE of 16.14%, which further highlight its operational efficiency and profitabili...

The Ensign Group Hits New 52-Week High of $179.27

2025-10-15 16:54:32

The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly above the S&P 500. The company showcases robust financial metrics, including a solid return on equity and low debt-to-equity ratio, alongside consistent positive results in sales and operating profit growth.

View All News